FDA Approves New First-Line TNBC Regimen - Top-Institutions - MDSpire

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

  • By

  • Kathryn Wighton

  • June 26, 2026

  • 3 min

Share

Top Institutions in Obgyn

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Oncology

  • #2

    Mayo Clinic Cancer Center
    Mayo Clinic Cancer Center

    Rochester, MN

    Key Differentiators

    • Multiple Myeloma

  • #3

    University of Wisconsin Carbone Cancer Center
    University of Wisconsin Carbone Cancer Center

    Madison, WI

    Key Differentiators

    • Multiple Myeloma

  • #4

    Feinberg School of Medicine, Northwestern University
    Feinberg School of Medicine, Northwestern University

    Chicago, IL

    Key Differentiators

    • Hematology and Medical Oncology

  • #5

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Myelodysplastic Syndromes

Original Source(s)

FDA Approves New First-Line TNBC Regimen

  • by Kathryn Wighton

  • June 26, 2026

Related Content

Surveillance May Reduce CIN 2 Overtreatment

Risk-based management may reduce unnecessary excisions in selected patients with CIN 2.

Correction: Endometrioid cancer associated with endometriosis: from the seed and soil theory to clinical practice

Epidemiology, outcomes of treatment, and survival of cervical cancer in Kazakhstan: a nationwide population-based study